摘要
The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which 50 cases received bevacizumab plus chemotherapy in both first-line and second-line therapies (Group A) and 51 cases received first-line cetuximab plus chemotherapy followed by second-line bevacizumab-containing regimens (Group B). The progression free survival (PFS) and overall survival (OS) from start of first-line (PFS 1nd and OS 1nd) and second-line (PFS 2nd and OS 2nd) therapy were compared between the two groups. PFS 1nd was comparable (10.0 vs 10.4 months; p=0.402), while PFS 2nd (4.6 vs 7.9 months; p=0.002), OS 1nd (26.8 vs 40.0 months; p=0.011), and OS 2nd (15.2 vs 22.3 months; p=0.006) were all poorer in group A compared with group B. Our study in combination with previous clinical data suggest that first-line application of cetuximab may provide a favorable condition for promoting the effect of subsequent bevacizumab, thus representing the optimal targeted therapy sequence in patients of RAS wild-type left-sided mCRC.
学科与关键词
- Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective studyMeng, Qianhao; Zhao, Jian; Yu, Yuanyuan; Wang, Ke; Ren, Jing; Xu, Chang; Wang, Yusheng*; Wang, Guangyu*BMC CANCER, 2023, 23(1): 191.被引 1
- CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.Xu, Jianming; Cao, Bangwei; Gu, Kangsheng; Bai, Yuxian; Li, Wei; Zhang, Jingdong; Liu, Caigang; Niu, Zuoxing; Zhang, Liangming; Zhong, Haijun; Luo, Suxia; Zhou, Jian-Wei; Liu, Tianshu; Gu, Yanhong; Lin, Jingguan; Deng, Yanhong; Chen, Chuangqi; Li, Yunfeng; Yang, Xiuli; Li, BihuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancerDing, K.; Liu, Y.; Song, Y.; Xu, D.; Li, J.; Wang, J.; Chen, X.; Lin, R.; Jiang, Y.; Zhang, Y.; Zhang, W.; Cheng, Y.; Wu, X.; Yuan, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
